Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Pegfilgrastim Formulations in Healthy Volunteers
NCT02589301Phase 1Completed
- Sponsor
- Eurofarma
- Start
- Nov 2015
- Primary completion
- Mar 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pegfilgrastim in neutropenia (2 arms), sponsored by Eurofarma. Primary endpoints: Peak Maximum Concentration in Plasma at 16 days, Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 16 days and 1 more. Started Nov 2015; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02589301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02589301.